[1] 沈琮, 陈文倩, 张相林. 替考拉宁治疗药物监测进展[J]. 中国医院用药评价与分析, 2019, 19(7):890-894,896.
[2] ZHOU L J, GAO Y Q, CAO W, et al. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections[J]. Infect Drug Resist,2018,11:29-36. doi:  10.2147/IDR.S146961
[3] 何丹, 董娜, 朱怀军, 等. 基于替考拉宁群体药物代谢动力学模型的个体化给药研究进展[J]. 临床药物治疗杂志, 2020, 18(5):38-42. doi:  10.3969/j.issn.1672-3384.2020.05.008
[4] 梁培, 郭晓芳. 重症感染患者替考拉宁血药谷浓度68例次监测分析[J]. 实用药物与临床, 2018, 21(5):553-556.
[5] 张荣格, 张瑞霞, 张弋. 替考拉宁的血药浓度监测及影响因素分析[J]. 中国药学杂志, 2019, 54(8):654-658.
[6] 吕佩瑜, 邓方斌, 林玮玮, 等. 替考拉宁在中国成人患者中的群体药动学研究[J]. 中国药学杂志, 2020, 55(8):616-622.
[7] 李芳, 蔡乐, 毛智, 等. 重症感染患者负荷剂量替考拉宁的血药浓度监测[J]. 临床药物治疗杂志, 2019, 17(11):44-48. doi:  10.3969/j.issn.1672-3384.2019.11.010
[8] DHARNIDHARKA V R, KWON C, STEVENS G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis[J]. Am J Kidney Dis,2002,40(2):221-226. doi:  10.1053/ajkd.2002.34487
[9] 周丽娟, 刘嘉, 曹巍, 等. 替考拉宁血药浓度监测对肺炎患者用药方案的指导意义探讨[J]. 中国医院药学杂志, 2017, 37(8):771-775.
[10] 胡萨萨, 尤海生, 金建霞, 等. 中性粒细胞缺乏伴发热患者应用替考拉宁抗感染的剂量监测及优化[J]. 河北医药, 2019, 41(23):3654-3658. doi:  10.3969/j.issn.1002-7386.2019.23.035
[11] 王冉冉, 马婧, 黄晓会. 重症感染患者替考拉宁血药谷浓度不达标的相关因素分析[J]. 中国药师, 2020, 23(3):494-496. doi:  10.3969/j.issn.1008-049X.2020.03.021
[12] KASAI H, TSUJI Y, HIRAKI Y, et al. Population pharmacokinetics of teicoplanin in hospitalized elderly patients using cystatin C as an indicator of renal function[J]. J Infect Chemother,2018,24(4):284-291. doi:  10.1016/j.jiac.2017.12.002
[13] KOZONO A, HIRAKI Y, ADACHI R, et al. Comparison of predictive accuracy of teicoplanin concentration using creatinine clearance and glomerular filtration rate estimated by serum creatinine or cystatin C[J]. J Infect Chemother,2016,22(5):314-318. doi:  10.1016/j.jiac.2016.01.024